"Advanced breast Cancer" trang 1 - tải miễn phí từ tailieunhanh
The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: A literature review

The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: A literature review
11    77    0
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
8    103    0
Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: Study protocol for a randomized controlled trial
7    54    1
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
15    30    1
Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study

Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study
13    10    1
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
14    35    1
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol
5    82    1
Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: A prospective registerbased study

Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: A prospective registerbased study
9    94    0
Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study
7    77    1
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study
8    39    1
Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial
7    52    1
Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
12    71    0
Factors predicting patient satisfaction in women with advanced breast cancer: A prospective study

Factors predicting patient satisfaction in women with advanced breast cancer: A prospective study
7    59    1
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy

Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy
8    63    1
Patterns of resource utilization and cost for postmenopausal women with hormonereceptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Patterns of resource utilization and cost for postmenopausal women with hormonereceptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe
12    40    1
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries
15    38    1
Trastuzumab in advanced breast cancer – a decade of experience in Germany

Trastuzumab in advanced breast cancer – a decade of experience in Germany
9    32    1
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study
10    43    1
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial
13    41    1
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: A multicenter retrospective study
10    27    3